您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > CE3F4
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CE3F4
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CE3F4图片
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍
CE3F4 是由 cAMP (Epac1) 直接激活的交换蛋白的选择性拮抗剂,对 Epac1 和 Epac2(B) 的 IC50 分别为 10.7 μM 和 66 μM。

Kinase experiment:

To determine Epac1 exchange activity, 200 nM of purified GST-Rap1A preloaded with bGDP are incubated at 22℃ in exchange buffer (50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 5 mM 1,4-dithioerythritol, 5% glycerol, 0.01% Nonidet P-40) in the presence of 100 nM purified GST-Epac1 or GST-Epac1-Cat; 20 μM unlabeled GDP; and defined concentrations of cAMP, cyclic nucleotide analogs, and test compounds (CE3F4). Experiments are performed in black 384-well plates in a final volume of 30 μL. bGDP fluorescence (excitation, 480 nm and emission, 535 nm) is measured using a multilabel plate reader[2].

Cell experiment:

Cells are cultured overnight in 96-well black-walled plates at 37℃ and 5% CO2, then washed twice in phosphate buffered saline. Cells are pre-incubated for two hours in glucose-free, modified KRBH supplemented with 0.05% fatty acid-free BSA at 37℃ and 5% CO2. The pre-incubation buffer is decanted, and cells are stimulated with 18 mM glucose in KRBH. Cells are incubated with or without inhibitors (CE3F4) in modified KRBH for 30 min at 37℃ and 5 % CO2 before glucose stimulation. The reactions are terminated at the indicated time points by decanting the treatments and fixing the cells with 4% formaldehyde. In experiments using pharmacological inhibitors, reactions are terminated 10 min after glucose stimulation is initiated. Total ERK and pERK is measured using the Phospho-ERK1 (T202/Y204) / ERK2 (T185/Y187) Cell-Based ELISA. Total ERK1/ERK2 is measured at 450 nm with excitation at 360 nm, and phosphorylated ERK1/ERK2 is measured at 600 nm with excitation at 540 nm, using a Synergy 4 Microplate Reader. The data are expressed as the ratio of pERK to total ERK then normalized and expressed as either fold over basal or % glucose response[3].

产品描述

CE3F4 is a selective antagonist of exchange protein directly activated by cAMP (Epac1), with IC50s of 10.7 μM and 66 μM for Epac1 and Epac2(B), respectively.

CE3F4 is a selective antagonist of Epac1, with IC50s of 10.7 μM and 66 μM for Epac1 and Epac2(B), respectively. CE3F4 is more active on Epac1 than (S)-stereoisomer ((S)-CE3F4, IC50, 56 μM), but less active than (R)-CE3F4 (IC50, 5.8 μM). CE3F4 (50 μM) shows more inhibitory activities against GEF activity of Epac1, than that of Epac2(AB) or Epac2(B)[1]. CE3F4 reduces the exchange activity of Epac1 induced by 007, with IC50 of 23 ± 3 μM. CE3F4 (40 μM) specifically inhibits Epac1 guanine nucleotide exchange activity without interference with Rap1 activity or Epac1-Rap1 interaction. CE3F4 has no influence on PKA activity. CE3F4 (20 μM) inhibits Epac-induced Rap1 activation in living cultured HEK293 cells[2]. CE3F4 (20 μM) significantly inhibits the late phase of ERK activation stimulated by glucose in INS-1 cells[3].

References:
[1]. Courilleau D, et al. The (R)-enantiomer of CE3F4 is a preferential inhibitor of human exchange protein directly activated by cyclic AMP isoform 1 (Epac1). Biochem Biophys Res Commun. 2013 Oct 25;440(3):443-8.
[2]. Courilleau D, et al. Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP-binding protein Epac. J Biol Chem. 2012 Dec 28;287(53):44192-202.
[3]. Pratt EP, et al. Ca2+ influx through L-type Ca2+ channels and Ca2+-induced Ca2+ release regulate cAMP accumulation and Epac1-dependent ERK 1/2 activation in INS-1 cells. Mol Cell Endocrinol. 2016 Jan 5;419:60-71.